Hospital
Jennie Edmundson Memorial Hospital
Jennie Edmundson Memorial Hospital was paid $9.83M by Medicaid between Jan 2018 and Dec 2024, across 100 billing codes. Its largest line is 99284, emergency room visit (serious) — 31% of everything it billed.
33Billing provider infoJENNIE EDMUNDSON MEMORIAL HOSPITAL
COUNCIL BLUFFS, IA 51503
COUNCIL BLUFFS, IA 51503
33aNPI1457448755assigned 10/06/2006
33bProvider typeGeneral Acute Care Hospital
28Total paid$9.83M
24GClaims223,803
24DCodes billed100
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Iowa
Rank by total paid#12 of 29
Median peer was paid$6.37M
This provider vs. median1.5×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,666 | $1.25M | |
| 2019 | 29,266 | $1.27M | |
| 2020 | 24,921 | $967K | |
| 2021 | 30,097 | $1.47M | |
| 2022 | 42,376 | $1.80M | |
| 2023 | 47,467 | $2.02M | |
| 2024incomplete | 24,010 | $1.05M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 31% | 14,091 | 13,129 | $3.08M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 29% | 19,916 | 18,871 | $2.88M |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | 8.5% | 7,724 | 7,152 | $834K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 6.9% | 1,912 | 1,723 | $678K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 5.9% | 6,915 | 6,540 | $578K |
| 71045 | Radiologic examination, chest; single view | 1.9% | 3,560 | 3,320 | $191K |
| 93306 | Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete | 1.9% | 641 | 604 | $185K |
| 96375 | Therapeutic injection; each additional sequential IV push | 1.8% | 4,925 | 4,350 | $176K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.7% | 785 | 743 | $166K |
| 71046 | Radiologic examination, chest; 2 views | 1.1% | 2,045 | 1,898 | $112K |
| 96361 | Intravenous infusion, hydration; each additional hour | 1.1% | 2,440 | 2,207 | $108K |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 1.0% | 1,572 | 1,019 | $100K |
88 more codes
| 80053 | Comprehensive metabolic panel | <1% | 27,430 | $74K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 1,469 | $72K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | <1% | 367 | $63K |
| 80061 | Lipid panel | <1% | 4,476 | $49K |
| 70450 | Computed tomography, head or brain; without contrast material | <1% | 916 | $45K |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 1,364 | $42K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 1,364 | $38K |
| 84443 | Thyroid stimulating hormone (TSH) | <1% | 2,723 | $37K |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 652 | $32K |
| 87480 | <1% | 2,019 | $31K | |
| 87660 | <1% | 2,019 | $29K | |
| 87510 | <1% | 2,019 | $29K | |
| 97597 | <1% | 358 | $25K | |
| J8499 | Prescription drug, oral, non chemotherapeutic, nos | <1% | 16,010 | $24K |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 156 | $19K |
| 80050 | General health panel | <1% | 356 | $17K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 2,011 | $16K |
| 90870 | <1% | 80 | $14K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 1,711 | $13K |
| 87634 | <1% | 1,147 | $9K | |
| 84439 | <1% | 993 | $8K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 20,455 | $8K |
| 87631 | <1% | 302 | $6K | |
| 41899 | Unlisted procedure, dentoalveolar structures | <1% | 29 | $6K |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 171 | $4K |
| 87081 | <1% | 470 | $3K | |
| J3490 | Unclassified drugs | <1% | 13,461 | $3K |
| 71250 | <1% | 37 | $3K | |
| 0352U | <1% | 907 | $3K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 737 | $1K |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 19 | $1K |
| 97530 | Therapeutic activities, direct patient contact, each 15 minutes | <1% | 41 | $1K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 194 | $1K |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 4,454 | $1K |
| 83655 | <1% | 67 | $928.22 | |
| 84702 | <1% | 1,453 | $872.62 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 5,648 | $795.91 |
| 87801 | Infectious agent detection by nucleic acid; amplified probe, multiple organisms | <1% | 14 | $737.62 |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 315 | $626.38 |
| 36415 | Collection of venous blood by venipuncture | <1% | 59 | $512.31 |
| 81001 | <1% | 7,934 | $505.63 | |
| 86769 | <1% | 13 | $505.56 | |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 | <1% | 515 | $500.00 |
| 86850 | <1% | 24 | $495.06 | |
| 93017 | <1% | 38 | $433.85 | |
| 83690 | <1% | 2,857 | $420.91 | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 40 | $261.05 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 119 | $246.84 |
| 86703 | <1% | 13 | $144.63 | |
| 85018 | <1% | 27 | $72.28 | |
| 87077 | <1% | 15 | $46.08 | |
| 83605 | <1% | 3,951 | $25.59 | |
| 87186 | <1% | 13 | $24.66 | |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 174 | $23.00 |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | <1% | 38 | $22.95 |
| 84484 | <1% | 2,062 | $13.70 | |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 4,539 | $9.10 |
| 85730 | <1% | 1,108 | $8.67 | |
| 81003 | <1% | 1,259 | $6.53 | |
| 83735 | <1% | 557 | $6.37 | |
| 85610 | <1% | 1,155 | $5.78 | |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 124 | $0.59 |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 3,163 | $0.31 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | 0% | 2,705 | $0.00 |
| J7050 | Infusion, normal saline solution, 250 cc | 0% | 1,509 | $0.00 |
| 84703 | 0% | 122 | $0.00 | |
| 83880 | 0% | 152 | $0.00 | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | 0% | 198 | $0.00 |
| 85379 | 0% | 165 | $0.00 | |
| 96376 | 0% | 28 | $0.00 | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | 0% | 271 | $0.00 |
| J1170 | Injection, hydromorphone, up to 4 mg | 0% | 15 | $0.00 |
| J2060 | Injection, lorazepam, 2 mg | 0% | 13 | $0.00 |
| 82962 | 0% | 16 | $0.00 | |
| 87040 | 0% | 14 | $0.00 | |
| 85027 | 0% | 16 | $0.00 | |
| 86141 | 0% | 15 | $0.00 | |
| A4217 | Sterile water/saline, 500 ml | 0% | 28 | $0.00 |
| J2270 | Injection, morphine sulfate, up to 10 mg | 0% | 592 | $0.00 |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | 0% | 2,008 | $0.00 |
| 84145 | 0% | 892 | $0.00 | |
| 85007 | 0% | 30 | $0.00 | |
| J7120 | Ringers lactate infusion, up to 1000 cc | 0% | 104 | $0.00 |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 0% | 27 | $0.00 |
| A4216 | Sterile water, saline and/or dextrose, diluent/flush, 10 ml | 0% | 29 | $0.00 |
| 81025 | 0% | 87 | $0.00 | |
| J7040 | Infusion, normal saline solution, sterile (500 ml = 1 unit) | 0% | 15 | $0.00 |
| J2310 | Injection, naloxone hydrochloride, per 1 mg | 0% | 15 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialFRANCIS, JEFF (VP FINANCE & CFO)
| Provider | Location | Paid |
|---|---|---|
| Jennie Edmundson Memorial Hospital | Council Bluffs, IA | $5.47M |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.